DOPF

DOPF
Clinical data
Other names	DOPF; 2,5-Dimethoxy-4-(3-fluoropropyl)amphetamine; 4-(3-Fluoropropyl)-2,5-dimethoxyamphetamine
Routes of; administration	Unknown
Pharmacokinetic data
Duration of action	Unknown
Identifiers
	IUPAC name 2-[4-(3-fluoropropyl)-2,5-dimethoxyphenyl]ethanamine;
PubChem CID	163192484;
ChemSpider	129558527;
CompTox Dashboard (EPA)	DTXSID001337046 ;
Chemical and physical data
Formula	C14H22FNO2
Molar mass	255.333 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COc1cc(CCCF)c(cc1CC(C)N)OC;
	InChI InChI=1S/C14H22FNO2/c1-10(16)7-12-9-13(17-2)11(5-4-6-15)8-14(12)18-3/h8-10H,4-7,16H2,1-3H3; Key:UIHSFMYQJAKMHD-UHFFFAOYSA-N;

DOPF, also known as 2,5-dimethoxy-4-(3-fluoropropyl)amphetamine, is a designer drug from the amphetamine and DOx families.^[1] It was first synthesised by Alexander Shulgin and David Nichols in 1989 but was never published at the time, and was finally disclosed in Daniel Trachsel's review of the field in 2013.^[1] It has a binding affinity (K_i) of 9 nM at the serotonin receptor 5-HT_2A but is not known to have been tested in humans.^[1] DOPF is a controlled substance in Canada under phenethylamine blanket-ban language.^[2]

References

1 2 3 4 5 Trachsel D, Lehmann D, Enzensperger C (2013). Phenethylamine Von der Struktur zur Funktion [Phenethylamine From structure to function] (in German). Nachtschatten Verlag AG. p. 778-780. ISBN 978-3-03788-700-4.
↑ "Controlled Drugs and Substances Act". Department of Justice Canada. Retrieved 19 January 2026.

This hallucinogen-related article is a stub. You can help Wikipedia by adding missing information.